chufangao/CTO huggingface dataset:
Clinical trial NCT04327401: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
Official title: COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)
Acronym: CoDEX
Sponsor: Hospital Sirio-Libanes (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial results, which was accepted by the CoDEX Steering Committee.
Enrollment: 299.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-13
Primary completion date: 2020-07-22
Completion date: 2020-07-22
Plan to share individual participant data: NO
Clinical trial NCT03795012: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients
Official title: A Multicenter, Randomized, Phase II Trial Evaluating the Efficacy of Eribulin Monotherapy and Eribulin Plus Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients After Progression on Endocrine Therapy (REVERT)
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment rate
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-30
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Plan to share individual participant data: NO
Clinical trial NCT04101890: The Healthy Baby Bottoms Study
Official title: The Healthy Baby Bottoms Study: A Trial of Theraworx Foam Formulation for the Prevention and Treatment of Diaper Dermatitis
Sponsor: Children's National Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Principal Investigator left the Institution and decision was made by funders to terminate the trial.
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-12
Primary completion date: 2021-01-02
Completion date: 2021-01-02
Plan to share individual participant data: NO
Clinical trial NCT03383146: A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
Official title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Relamorelin program is being terminated solely based on a business decision.
Enrollment: 450.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-01
Primary completion date: 2020-11-05
Completion date: 2020-11-05
Baseline population: Intent-to-treat (ITT) Population included all randomized participants.
Clinical trial NCT03712930: Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency
Official title: A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to revisit the development approach for prostate cancer.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-02-05
Primary completion date: 2020-08-06
Completion date: 2020-09-02
Plan to share individual participant data: YES
Clinical trial NCT03232112: Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?
Official title: Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?
Acronym: EXALT
Sponsor: Psychiatric Centre Rigshospitalet (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-07
Primary completion date: 2020-03-15
Completion date: 2020-10-05
Plan to share individual participant data: YES
IPD sharing description: At the start and at the end of the study a blood sample (9ml) and a urine sample (7.2ml) will be stored in a biobank for future research. The patients will be asked to give a separate written consent. Using this biobank in the future will require a new approval from the Danish Data Protection Agency.
Clinical trial NCT03587129: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Official title: Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Sponsor: First Affiliated Hospital of Harbin Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No patient enter this study.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-10
Primary completion date: 2020-06-14
Completion date: 2020-06-14
Plan to share individual participant data: NO
IPD sharing description: The investigators have no other clinical trial about ovarian cancer
Clinical trial NCT04498273: COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
Official title: COVID-19 Outpatient Thrombosis Prevention Trial A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID Adults Not Requiring Hospitalization at Time of Diagnosis
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: an event rate lower than anticipated
Enrollment: 657.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-07
Primary completion date: 2021-08-05
Completion date: 2021-08-05
Limitations and caveats: Early termination leads to a small number of subjects being analyzed.
Plan to share individual participant data: NO
Clinical trial NCT04968951: Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
Official title: REFOCUS: Refined Fecal Microbiota Transplantation (FMT) Delivered by Oral Capsules for Induction of Remission in Mild to Moderate Ulcerative Colitis - a Phase I Study
Acronym: REFOCUS
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: insufficient funding
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-10
Primary completion date: 2022-08-22
Completion date: 2022-08-22
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available
Clinical trial NCT04173611: Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers
Official title: Phase 1, Randomized, Double-Blind, Active and Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers.
Sponsor: Pacira Pharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated for strategic and administrative reasons
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-08
Primary completion date: 2020-12-07
Completion date: 2020-12-07
Clinical trial NCT02662894: Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Official title: Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Sponsor: EMS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-31
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Clinical trial NCT03763175: Efficacy and Safety of SYN-010 in IBS-C
Official title: Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Interim Futility Analysis
Enrollment: 59.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-24
Primary completion date: 2020-10-09
Completion date: 2020-10-09
Clinical trial NCT05178654: Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.
Official title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS BALANCE, METABOLISM AND EXCRETION OF [14C]PF-07321332 IN HEALTHY MALE PARTICIPANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Based on various healthy authorities feedback on PAXLOVID submission, this study is no longer required.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-22
Primary completion date: 2022-04-01
Completion date: 2022-04-01
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04814537: Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques
Official title: A Trial to Determine the Optimal Bupivacaine Dose for Initiation of Labor Epidural Pain Relief
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-25
Primary completion date: 2022-03-23
Completion date: 2022-03-23
Plan to share individual participant data: NO
Clinical trial NCT03789214: Medical Management of Sleep Disturbance During Opioid Tapering
Official title: Medical Management of Sleep Disturbance During Opioid Tapering
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 90.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-07-01
Primary completion date: 2021-06-10
Completion date: 2021-06-10
Plan to share individual participant data: NO
Clinical trial NCT04085393: Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Official title: Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Breakthrough Nausea and Vomiting (CINV) in Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Phase II Clinical Trial
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: sponsor withdrew study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-15
Primary completion date: 2020-08-15
Completion date: 2022-12-01
Plan to share individual participant data: NO
Clinical trial NCT05439941: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials
Official title: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous Phase 2 And 3 EDP1815 Trials
Sponsor: Evelo Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Parent Study (NCT05121480) did not meet the primary endpoint.
Enrollment: 287.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-06-06
Primary completion date: 2023-05-25
Completion date: 2023-06-07
Plan to share individual participant data: NO
Clinical trial NCT03263091: Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Sponsor: FibroGen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study did not meet its primary efficacy endpoint.
Enrollment: 184.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-29
Primary completion date: 2023-03-09
Completion date: 2023-06-20
Baseline population: The safety analysis set included all participants who received at least 1 dose of study drug.
Limitations and caveats: Study did not meet its primary efficacy endpoint; hence, the study was terminated early.
Plan to share individual participant data: NO
Clinical trial NCT04261036: Vitamin C for the Prevention of UTI in Women Who Undergo Elective Gynecological Surgeries
Official title: Vitamin C for the Prevention of Catheter-associated Urinary Tract Infections in Women Who Undergo Elective Gynecological Surgeries: a Study Protocol for a Randomized Double Blinded Controlled Trial.
Sponsor: American University of Beirut Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Unfortunately, the economic crisis in Lebanon precluded utilization of available funding to recruit patients at the specified institution. No patients were recruited.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-20
Primary completion date: 2021-07-01
Completion date: 2021-10-01
Plan to share individual participant data: NO
Clinical trial NCT05584332: A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
Official title: A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years
Sponsor: Shanghai Bovax Biotechnology Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Strategic adjustment
Enrollment: 3131.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-09
Primary completion date: 2023-03-23
Completion date: 2023-03-23
Clinical trial NCT04045145: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
Official title: A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
Sponsor: Neurocrine Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-12
Primary completion date: 2021-07-02
Completion date: 2021-07-02
Baseline population: All participants who received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT03163667: CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Acronym: ENTRATA
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 69.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-06
Primary completion date: 2019-04-26
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT02624856: Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty
Official title: Prospective, Randomized, Double-Blinded, Allocation Concealed Study Comparing the Efficacy of Liposomal Bupivacaine Over Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Primary Total Knee Arthroplasty
Sponsor: Albany Medical College (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-30
Primary completion date: 2017-11-30
Completion date: 2020-01-01
Clinical trial NCT00134030: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Official title: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy
Acronym: EURAMOS-1
Sponsor: Children's Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1334.0 (ACTUAL)
Number of arms: 4.0
Start date: 2005-11-14
Primary completion date: 2015-01-31
Completion date: 2022-09-30
Limitations and caveats: In the good response patients (randomised to MAP-GR or MAPifn), 128 of 357 MAPifn patients completed the planned protocol treatment. Among poor response patients (randomised to MAP-PR or MAPie), 42% of registered patients were not randomised. Further patients were registered to the trial and joined a treatment cohort for follow-up but declined to join the randomisation or were not eligible. The data for these non-randomised patients are not presented here.
Clinical trial NCT04598321: BrUOG 390: Neoadjuvant Treatment With Talazoparib
Official title: BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: termination of research grant agreement
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-29
Primary completion date: 2022-11-30
Completion date: 2022-12-06
Clinical trial NCT04220892: Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma
Official title: Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for the Treatment of Patients With High Grade Glioma
Sponsor: Saint John's Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-08
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Plan to share individual participant data: NO
Clinical trial NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Official title: A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.
Enrollment: 538.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-26
Primary completion date: 2024-03-21
Completion date: 2024-03-21
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03418805: To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers
Official title: A Randomized, 4-way Crossover Study to Evaluate the Food Effect and the Absorption Profile of Investigational Product of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets 200 mg in Normal Healthy Volunteers
Sponsor: Overseas Pharmaceuticals, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's consideration of product development strategies
Enrollment: 31.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-11
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03025087: Hydroxychloroquine and Cognitive Function After Surgery
Official title: Hydroxychloroquine and Cognitive Function After Surgery
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Showed no benefit
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-06-19
Primary completion date: 2023-05-22
Completion date: 2024-04-19
Baseline population: Data not collected on eight participants. There was no enrollment in Phase 3, Phase 4, or Phase 5.
Plan to share individual participant data: NO
Clinical trial NCT04746339: Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Official title: Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial
Acronym: APOLLO
Sponsor: Brazilian Clinical Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Due to the decrease in COVID cases and in the recruitment rate, and DSMB orientation.
Enrollment: 411.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-04
Primary completion date: 2022-05-13
Completion date: 2022-05-30
Plan to share individual participant data: YES
IPD sharing description: All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.
Clinical trial NCT05033561: Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
Official title: A Phase III Open-label Randomized Controlled Study to Evaluate the Safety and Immunogenicity of nOPV2 at Different Intervals of Administration in Infants
Sponsor: Fidec Corporation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 905.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-16
Primary completion date: 2022-05-24
Completion date: 2022-10-25
Plan to share individual participant data: NO
Clinical trial NCT02336074: Research In Viral Eradication of HIV Reservoirs
Official title: Research In Viral Eradication of HIV Reservoirs
Acronym: RIVER
Sponsor: Imperial College London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-27
Primary completion date: 2017-11-15
Completion date: 2023-03-31